NCT07486115
Not yet recruiting
Phase 1
A Phase 1, Randomised, Single-blind, Placebo-controlled Trial to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BI 3814916 in Healthy Male and Female Subjects
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 136
- Locations
- 1
- Primary Endpoint
- Occurrence of any treatment-emergent adverse events (AEs) assessed as drug-related by the investigator
Overview
Brief Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3814916 in healthy male and female trial participants.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age of 18 to 65 years (inclusive) at the time of screening
- •Body mass index (BMI) of 18.5 to 30.0 kg/m² (inclusive) at screening
- •Signed and dated written informed consent in accordance with ICH Harmonized Guideline for Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
- •Agree to refrain from strenuous or unusual exercise/activity (for example heavy lifting, weight training, intense aerobics classes, etc.) for at least 72 hours prior to study visits.
- •Agree to abstain from alcoholic beverages and/or soft drugs (e.g., marijuana) for at least 48 hours prior to study visits.
- •Further inclusion criteria apply.
Exclusion Criteria
- •Any finding in the medical examination (including blood pressure (BP), pulse rate (PR), temperature or electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant by the investigator
- •Repeated measurement of systolic BP outside the range of 90 to 140 mmHg, diastolic BP outside the range of 45 to 90 mmHg, or PR outside the range of 45 to 100 beats per minute (bpm)
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders that the investigator considers to be of clinical relevance Further exclusion criteria apply.
Outcomes
Primary Outcomes
Occurrence of any treatment-emergent adverse events (AEs) assessed as drug-related by the investigator
Time Frame: up to 111 days
Secondary Outcomes
- Part B: Maximum measured concentration of the analyte in serum at steady state (Cmax,ss), if steady state can be reasonably assumed(up to 108 days)
- Part A: Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity (AUC0-∞)(up to 72 days)
- Part A: Maximum measured concentration of the analyte in serum (Cmax)(up to 72 days)
- Part B: Area under the concentration-time curve of the analyte in serum over the dosing interval tau at steady state (AUCτ,ss), if steady state can be reasonably assumed(up to 108 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A First-in-human Trial of GRT7041 in Healthy ParticipantsNCT07289776Grünenthal GmbH70
Recruiting
Phase 1
A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846Alnylam Pharmaceuticals156
Recruiting
Phase 1
Phase I Study of HXN6005 in Adult Healthy ParticipantsNCT07449741Helixon Biotechnology (Suzhou) Co., Ltd32
Completed
Phase 1
A Study of HS-10518 in Healthy Adult Premenopausal Females in ChinaNCT07264192West China Second University Hospital60
Recruiting
Phase 1
Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy VolunteersNCT07347678Ikaria Bioscience Pty Ltd60